Custom service

Recombinant Monoclonal Antibody Production

A clonal, sequence-defined supply that does not depend on a cell line's memory.

Timeline: 6–10 weeks — to stable poolConsistency: Lot-to-lot — within 10% titreScale: 100 mg–10 g — stable pool or clone

A hybridoma can lose productivity; a recombinant monoclonal cannot, because the productivity is encoded in a plasmid and a stable integrant rather than in a chromosome that may be lost. That is the reason therapeutic and diagnostic programmes convert their hybridomas to recombinant form once the sequence is known: the reagent becomes a specification that any qualified facility can reproduce.

Production goes through stable pool or stable clone. A stable pool is generated by transfection with a selectable marker and selection for two to three weeks, giving a heterogeneous population with a good average titre and a fast timeline. A stable clone requires limiting dilution or semi-solid cloning after selection, adding four to six weeks but giving a defined, bankable line with predictable productivity.

The molecule itself is chosen deliberately. Isotype, Fc silencing or enhancement, and host cell determine the effector profile and the glycosylation. For a reagent, HEK293-derived IgG1 is usually sufficient; for a programme moving toward clinical use, CHO with a characterised glycan profile and a documented cell bank is the appropriate choice.

Service Highlights

Where it fits

Recombinant monoclonal production is the correct choice for any antibody that must be supplied repeatedly over years: diagnostic calibrators, reference standards, in vivo reagents and therapeutic candidates. It also decouples supply from a hybridoma's viability, which matters when the original clone is ageing or contaminated.

It requires a sequence, so a hybridoma must be sequenced first, and it is more expensive per milligram than a single purification at small scale. For a one-off research batch, transient expression is usually sufficient.

Documentation and QC

Release testing covers identity by peptide mapping or mass spectrometry, purity by SDS-PAGE and SEC-HPLC, charge variants by IEX, glycan profile by HILIC, residual host cell protein and DNA, and antigen binding by ELISA or SPR. Cell banks are tested for sterility, mycoplasma and identity.

Frequently asked questions

Should we choose a pool or a clone?

A pool is faster and adequate for research supply. A clone is required when a master cell bank must be documented, when productivity must be predictable over years, or when a regulator will review the process.

How consistent is batch-to-batch yield?

Within about 10% for a well-characterised pool under fixed process parameters. The variation that remains comes from cell age and from media lot, both of which are controlled.

Can the cell line be transferred?

Yes. The master cell bank, plasmid archive and batch records are transferred under an agreement, and we support technical transfer to your facility.

Send the sequence and tell us the intended use. If the antibody is a research reagent, a stable pool is enough; if it will be regulated, we will scope a clonal line and a documented bank from the start.

Service Highlights

  • Stable pool or clonal line. Pool for speed at 4–6 weeks, clone for a bankable master cell line at 8–12 weeks.
  • Defined isotype and Fc. IgG1, IgG2, IgG4 with S228P, or effector-silenced variants, selected for the intended application.
  • Host cell matched to purpose. HEK293 for research reagents, CHO for programmes requiring a manufacturing-relevant glycan profile.
  • Documented cell bank. Master and working banks with passage number, viability and productivity recorded.
  • Consistent titre. Fed-batch process with defined parameters, so successive runs fall within a narrow range.
  • Sequence and plasmid archive. Full documentation, so the antibody can be transferred to another facility without re-development.

How the work runs

  1. Format and host selection

    Isotype, Fc engineering and host cell are agreed on the basis of the intended use, not on what is fastest.

  2. Vector construction

    Heavy and light chains cloned into a dual-promoter or two-plasmid system with a selectable marker such as GS or DHFR.

  3. Transfection and selection

    CHO or HEK293 cells transfected, then selected under methotrexate or methionine sulfoximine to amplify expression.

  4. Pool or clone generation

    Stable pool expanded directly, or single-cell cloned by limiting dilution or semi-solid matrix for a defined line.

  5. Process development

    Small-scale fed-batch runs to set feeding, pH and harvest timing, with titre and glycan profile compared across runs.

  6. Production and QC

    Preparative culture, protein A purification, formulation, and release testing including SEC-HPLC, SDS-PAGE, glycan analysis and binding.

Specifications & timeline

Timeline
6–10 weeks — to stable pool
Consistency
Lot-to-lot — within 10% titre
Scale
100 mg–10 g — stable pool or clone
Host
CHO-K1, CHO-S, HEK293
Expression system
GS or DHFR selection with amplification
Scale
100 mg to 10 g per batch
Titre
0.5–5 g/L in stable pools after amplification
Timeline
6–10 weeks to stable pool, 10–16 weeks to cloned line
Deliverables
Purified antibody, master cell bank, batch record, glycan and purity data, plasmid archive

Related Products

Next step

Tell us the target, we will tell you what is feasible

Send the sequence, assay format and sensitivity you need. You will get a technical assessment — recommended platform, timeline and the risks worth knowing before you commit budget.